Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial The model included current ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results